



Perspective

A New Initiative on Precision Medicine

Francis S. Collins, M.D., Ph.D., and Harold Varmus, M.D.

February 26, 2015

N Engl J Med 2015; 372:793-795

DOI: 10.1056/NEJMp1500523

Article

Figures/Media

Metrics

5 References

2747 Citing Articles

7 Comments

Article



Audio Interview



Interview with Dr. Francis Collins on what to expect from the recently announced Precision Medicine Initiative. (10:07)

[Download](#)

“Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.”

— President Barack Obama, State of the Union Address, January 20, 2015



RESIDENT OBAMA HAS LONG EXPRESSED A STRONG CONVICTION THAT SCIENCE

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. [X](#)

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

The concept of precision medicine — prevention and treatment strategies that take individual variability into account — is not new¹; blood typing, for instance, has been used to guide blood transfusions for more than a century. But the prospect of applying this concept broadly has been dramatically improved by the recent development of large-scale biologic databases (such as the human genome sequence), powerful methods for characterizing patients (such as proteomics, metabolomics, genomics, diverse cellular assays, and even mobile health technology), and computational tools for analyzing large sets of data. What is needed now is a broad research program to encourage creative approaches to precision medicine, test them rigorously, and ultimately use them to build the evidence base needed to guide clinical practice.

The proposed initiative has two main components: a near-term focus on cancers and a longer-term aim to generate knowledge applicable to the whole range of health and disease. Both components are now within our reach because of advances in basic research, including molecular biology, genomics, and bioinformatics. Furthermore, the initiative taps into converging trends of increased connectivity, through social media and mobile devices, and Americans' growing desire to be active partners in medical research.

Oncology is the clear choice for enhancing the near-term impact of precision medicine. Cancers are common diseases; in the aggregate, they are among the leading causes of death nationally and worldwide, and their incidence is increasing as the population ages. They are also especially feared, because of their lethality, their symptoms, and the often toxic or disfiguring therapies used to treat them. Research has already revealed many of the molecular lesions that drive cancers, showing that each cancer has its own genomic signature, with some tumor-specific features and some features common to multiple types. Although cancers are largely a consequence of accumulating genomic damage during life, inherited genetic variations contribute to cancer risk, sometimes profoundly. This new understanding of oncogenic mechanisms has begun to influence risk assessment, diagnostic categories, and therapeutic strategies, with increasing use of drugs and antibodies designed to counter the influence of specific molecular drivers. Many targeted therapies have been (and are being) developed, and several have been shown to confer benefits, some of them spectacular.² In addition, novel immunologic approaches have recently produced some profound responses, with signs that molecular signatures may be strong predictors of benefit.³

These features make efforts to improve the ways we anticipate, prevent, diagnose, and treat cancers both urgent and promising. Realizing that promise, however, will require the many different efforts reflected in the President's initiative. To achieve a deeper understanding of cancers and discover additional tools for molecular diagnosis, we will need to analyze many more cancer genomes. To hasten the adoption of new therapies, we will need more clinical trials with novel designs⁴ conducted in adult and pediatric patients and more reliable models for preclinical testing. We will also need to build a “cancer knowledge network” to store the resulting molecular and medical data in digital form and to

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. 

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

heterogeneity of tumors, insufficient means for monitoring responses and tumor recurrence, and limited knowledge about the use of drug combinations.

Precision medicine's more individualized, molecular approach to cancer will enrich and modify, but not replace, the successful staples of oncology — prevention, diagnostics, some screening methods, and effective treatments — while providing a strong framework for accelerating the adoption of precision medicine in other spheres. The most obvious of those spheres are inherited genetic disorders and infectious diseases, but there is promise for many other diseases and environmental responses.

The initiative's second component entails pursuing research advances that will enable better assessment of disease risk, understanding of disease mechanisms, and prediction of optimal therapy for many more diseases, with the goal of expanding the benefits of precision medicine into myriad aspects of health and health care.

The initiative will encourage and support the next generation of scientists to develop creative new approaches for detecting, measuring, and analyzing a wide range of biomedical information — including molecular, genomic, cellular, clinical, behavioral, physiological, and environmental parameters. Many possibilities for future applications spring to mind: today's blood counts might be replaced by a census of hundreds of distinct types of immune cells; data from mobile devices might provide real-time monitoring of glucose, blood pressure, and cardiac rhythm; genotyping might reveal particular genetic variants that confer protection against specific diseases; fecal sampling might identify patterns of gut microbes that contribute to obesity; or blood tests might detect circulating tumor cells or tumor DNA that permit early detection of cancer or its recurrence.

Such innovations will first need to be tested in pilot studies. We will initially want to take advantage of the rare settings where it is already possible to collect rich information through clinical trials, electronic medical records, and other means.

Ultimately, we will need to evaluate the most promising approaches in much larger numbers of people over longer periods. Toward this end, we envisage assembling over time a longitudinal “cohort” of 1 million or more Americans who have volunteered to participate in research. Participants will be asked to give consent for extensive characterization of biologic specimens (cell populations, proteins, metabolites, RNA, and DNA — including whole-genome sequencing, when costs permit) and behavioral data, all linked to their electronic health records. Qualified researchers from many organizations will, with appropriate protection of patient confidentiality, have access to the cohort's data, so that the world's brightest scientific and clinical minds can contribute insights and analysis. These data will also enable observational studies of drugs and devices and potentially prompt more rigorous interventional studies that address specific questions.

Such a varied array of research activities will propel our understanding of diseases — their origins and

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. 

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

The research cohort will be assembled in part from some existing cohort studies (many funded by the NIH) that have already collected or are well positioned to collect data from participants willing to be involved in the new initiative. Creating this resource will require extensive planning to achieve the appropriate balance of participants, develop new approaches to participation and consent, and forge strong partnerships among existing cohorts, patient groups, and the private sector. It will also be crucial to carefully examine the successes and shortfalls of other longitudinal cohort studies.

Achieving the goals of precision medicine will also require advancing the nation's regulatory frameworks. To unleash the power of people to participate in research in innovative ways, the NIH is working with the Department of Health and Human Services to bring the Common Rule, a decades-old rule originally designed to protect research participants,⁵ more in line with participants' desire to be active partners in modern science. To help speed the translation of such discoveries, the Food and Drug Administration is working with the scientific community to make sure its oversight of genomic technology supports innovation, while ensuring that the public can be confident that the technology is safe and effective.

Although the precision medicine initiative will probably yield its greatest benefits years down the road, there should be some notable near-term successes. In addition to the results of the cancer studies described above, studies of a large research cohort exposed to many kinds of therapies may provide early insights into pharmacogenomics — enabling the provision of the right drug at the right dose to the right patient. Opportunities to identify persons with rare loss-of-function mutations that protect against common diseases may point to attractive drug targets for broad patient populations. And observations of beneficial use of mobile health technologies may improve strategies for preventing and managing chronic diseases.

Ambitious projects like this one cannot be planned entirely in advance; they should evolve in response to scientific and medical findings. Much of the necessary methodology remains to be invented and will require the creative and energetic involvement of biologists, physicians, technology developers, data scientists, patient groups, and others. The efforts should ideally extend beyond our borders, through collaborations with related projects around the world. Worldwide interest in the initiative's goals should motivate and attract visionary scientists from many disciplines.

This initiative will also require new resources; these should not compete with support of existing programs, especially in a difficult fiscal climate. With sufficient resources and a strong, sustained commitment of time, energy, and ingenuity from the scientific, medical, and patient communities, the full potential of precision medicine can ultimately be realized to give everyone the best chance at good health.

Funding and Disclosures

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. 

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

Author Affiliations



From the National Institutes of Health (F.S.C.) and the National Cancer Institute (H.V.) — both in Bethesda, MD.

Supplementary Material



[Disclosure Forms](#) PDF 113KB

References (5)



1. National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press, 2011 (<http://www.nap.edu/catalog/13284/toward-precision-medicine-building-a-knowledge-network-for-biomedical-research>).
[Google Scholar](#)
2. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. *Nature* 2010;467:543-549
[Crossref](#) [Web of Science](#) [Medline](#) [Google Scholar](#)
3. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014;371:2189-2199
[Free Full Text](#) [Web of Science](#) [Medline](#) [Google Scholar](#)
4. Abrams J, Conley B, Mooney M, et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. *Am Soc Clin Oncol Educ Book* 2014:71-6.
[Google Scholar](#)
5. Department of Health and Human Services. Federal Policy for the Protection of Human Subjects ('Common Rule'), 1991 (<http://www.hhs.gov/ohrp/humansubjects/commonrule>).
[Google Scholar](#)

[Close References](#)

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. 

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

Comments (7)



ANURAG AGRAWAL ▾

Mar 03, 2015

Will Precision Medicine be Accurate and Reliable

Drs Collins and Varmus provide a glimpse of the coming revolution in medicine but a question springs to mind about the nomenclature "Precision Medicine". It seems that what our patients want are accurate and reliable predictions; but precision is not in itself accuracy or reliability. It is indeed quite possible to be precise, down to single nucleotide variations or transcript copies, without any discernible increase in intended predictive accuracy. Further, given the variability across platforms and methods, one cannot always even be certain that apparently precise measurements reliably measure what they purport to measure. One wonders then, whether the term 'precision medicine' has been created to allow for the fact that while we can make increasingly precise estimation of the individual components of biological machinery, accurate or reliable predictions regarding the system await further understanding and invention; especially in accounting for stochasticity. Nevertheless, it is a much needed beginning and if executed well, hopefully the dawn of a new age in biomedical research

CHEW BOON HOW ▾

Feb 26, 2015

Precision Medicine- precised on what?

Precision Medicine as conceptualised and defined is very exciting and may open up a whole new era of medicine.

It is both intriguing and essential to clarify the term precision. I learned from the article that the precision refers to the precisely biological make-up of an individual, that once precisely identified, could be treated with precise treatment. Is this possible? Knowing the indefinite biological variations and possibilities in human beings, many genotypes do not necessarily link to certain phenotypes. Thus, absolute precision is on shaky ground. A widely effective and safe therapy is not to be discarded.

Maybe precision in identifying the actual cause of a disease, down to the aetiological agent/s specific characteristics, is going to be more practically useful. Diseases from unhealthy life-styles and behaviors would pose great challenge to Precision Medicine to influence. This is because life-style sprouting from personal value in life, which is hugely associated with perception of quality of life, and is greatly influenced by personal beliefs.

Ultimate purpose of medical care is to help sick people well. There is a continual debate on wellness and health.

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. 

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

The study design includes a serious error because the patients will not be selected at random. Even a large study population does not guarantee the results will adequately reflect any disease in the whole population. In practice the people included in the study must satisfy some random inclusion criteria such as by surviving long enough to allow for follow-up, being able to afford the necessary medical care, knowledge of family history, etc. Despite these limitations, it is essential that there be some effort to insure that random sampling is a basic building block in the study design so that treatment results come from an unbiased sample of some population.

Bernard Friedenson, PhD
Dept Biochemistry & Molecular Genetics
College of Medicine
University IL Chicago

MIKE FERNANDES ▾

Feb 26, 2015

Need for Precision Regulations

We congratulate Collins and Varmus for advancing the concept of precision medicine. In solid cancer, precision science has been long practiced by bench scientists. However, the dismal regulatory outcomes can be explained by the lack of precision regulations. For too long, approval has been based on the RECIST convention, namely tumor shrinkage. This, despite the universal recognition that the tumor shrinkage endpoint is a relic of the cytotoxic's era, and by definition is not a precision endpoint.

Failures in development may logically be attributed to a mismatch between precision science and imprecise regulations. This point has been clearly and elegantly explained by the authors: achieving the goals of precision medicine will also require advancing the nation's regulatory frameworks. Without this, and as evidenced by recent decisions of Big Pharma to de-emphasize their oncology franchise, we predict that anticancer R&D will wither on the vine. (Clin Transl Oncol. 2015 Jan; 17(1):1-10)

Professor Jan Brabek, PhD, Dept of Cell Biology, Charles University, Prague
Michael Fernandes, MD, Medbase, Chapel Hill, NC 27514

SERGIO STAGNARO, MD ▾

Feb 25, 2015

Obama's Precision Medicine? Single Patient Based Medicine.

In my opinion, Obama's worthy precision Medicine must be beneficial to everyone, that is, such as Medicine has to be applied on a very large scale. As a consequence, it must unavoidably be clinical in nature, rather than Laboratory- and Image Department-Dependent. In addition, to limit the costs of NHS this original Medicine must be based on the constitutions and related inherited real risks of any individual, bedside recognized with a common stethoscope from birth. What's the sense of researching blood glucose in those without diabetic Constitution, or the search for oncological markers in those who are not involved by Oncological Terrain, or requiring ECG and Echocardiogram to those without CAD Inherited Real Risk. In conclusion, Obama's Medicine must be the SPBM, i.e., Single Patient Based Medicine

1) Stagnaro S., West PJ., Hu FB., Manson JE., Willett WC. Diet and Risk of Type 2 Diabetes. N Engl J Med. 2002 Jan 24;346(4):297-298. [Medline] ;

2) Sergio Stagnaro and Simone Caramel. The Inherited Real Risk of Coronary Artery Disease. Nature DC

THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. 

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

More about

CANCER

HEALTH IT

HEALTH CARE DELIVERY

PUBLIC HEALTH

DIABETES

HEMATOLOGY/ONCOLOGY

TREATMENTS IN ONCOLOGY

More from the week of February 26, 2015




ORIGINAL ARTICLE

ity — Clinical Implications of Animal Models 2014 MERS-CoV Outbreak in Jeddah — A Link to H
s I.K. Oboho and Others

Tap into
groundbreaking
research and
clinically relevant
insights

SUBSCRIBE

Already a subscriber? [Sign In](#) or [Renew](#)



THIS SITE USES COOKIES to personalize content, to measure website and advertising performance, and to present relevant advertising. ✕

By continuing to use our site, you accept the use of these cookies. To learn more, please visit our [Cookie Information](#) page.

